幽门螺杆菌与中青年缺铁性贫血关系的临床研究

目的:探讨幽门螺杆菌(HP)感染与缺铁性贫血(IDA)的关系以及HP相关性IDA治疗的有效方法。方法:对132例有上消化道症状的中青年患者进行内镜下组织病理检查,胃黏膜活检标本快速尿素酶试验,同时所有患者作血常规,血清铁(SI),血清铁蛋白(SF),血清HP抗体(HP-IgG)检测。将HP感染伴慢性胃炎的IDA患者(36例)随机分成A,B2组,A组给予铁剂联合HP根治治疗,B组仅给予HP根治治疗,治疗后复查上述血液学指标。结果:HP感染的92例患者中IDA者有52例,IDA的患病率为56.5%;40例无HP感染患者中IDA者有6例,IDA的患病率为15.0%,两者相比差异有统计学意义(P<0.05)。58例IDA患者中,有52例为HP感染,HP感染率为89.7%;74例非IDA患者中,有40例为HP感染,HP感染率为54.1%,两者相比差异有统计学意义(P<0.05)。A,B2组治疗前后其血红蛋白(Hb),SI,SF均有显著性恢复,且A组比B组上述血液学指标差异有统计学意义。结论:HP感染可能为中青年IDA的病因之一,铁剂联合根治HP的治疗能显著提高中青年HP相关性IDA的治疗效果。

Clinical study on relationship of helicobacter pylori infection with iron deficiency anemia among young and middle aged patients

Objective:To explore the relationship between Helicobacter Pylori(HP) infection and iron deficiency anemia(IDA) and the new method to treat IDA related with HP infection.Method:132 young and middle aged patients of upper digestive tract symptom were investigated with gastroscopy and rapid urease test. Simultaneously all were measured with blood routine examination, serum iron(SI), serum ferritin(SF), serum HP-Immune globulin G(HP-IgG). 36 patients of HP infection with IDA and chronic gastritis were randomly classified into two groups. Group A was treated with oral iron supplement in conjunction with HP eradication therapy. Group B was given HP eradication therapy only.Result:In 92 patients with HP infection 52 cases were patients with IDA. The prevalence rate of IDA is 56.5%. In 40 patients without HP infection 6 cases were patients with IDA. The prevalence rate of IDA is 15.0%. Significant difference existed ketween the two groups.(P<0.05) In 58 patients with IDA 52 case were patients with HP infection .HP infection rate was 89.7%. In 74 patients with non-IDA 40 cases were patients with HP infections. HP infection rate was 54.1%. Significant difference existed between the two groups (P<0.05). In two groups hemoglobin(Hb), SI, SF were recovered significantly.Conclusion:HP infection may be one of the causes of IDA among young and middle aged patients. Oral iron supplement in conjunction with HP eradication therapy can significantly enhance the therapy results among young and middle aged IDA with chronic gastritis and it is effective for patients with IDA.